|
|
News Breaks
|
February 10, 2012
|
| 04:58 EDT |  | SNY, OSIR |
| theflyonthewall.com: | Osiris Therapeutics provides update regarding the Genzyme/Sanofi relationship | | Osiris Therapeutics (OSIR) provided an update on the status of the development and commercialization agreement with Genzyme, a Sanofi (SNY) company. On Feb. 8, Sanofi issued a press release, which included an update on their R&D pipeline, stating that it has "discontinued" its project with Prochymal for graft versus host disease. The statement issued by Sanofi was made without consultation with or knowledge of Osiris. Osiris has not received any notification from Sanofi regarding the discontinuation of the agreement in place between the two companies. Through its legal counsel, Osiris has advised Sanofi that Osiris is treating these public statements as Sanofi's election to terminate the agreement. The agreement provides that in this instance all rights to Prochymal revert back to Osiris without compensation to Sanofi, and Osiris is free to commercialize or enter into commercialization agreements for Prochymal with other parties without restriction. :theflyonthewall.com |
|
|
News For OSIR;SNY From The Last 14 Days Check below for free stories on OSIR;SNY the last two weeks.
There are 15 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 25, 2012
|
| 14:01 EDT | | SNY |
| | 14:00 EDT | | SNY |
|
|
May 21, 2012
|
| 07:38 EDT |  | SNY |
|
|
May 18, 2012
|
| 09:00 EDT |  | OSIR |
| theflyonthewall.com: | Osiris Therapeutics rises 8.9% | | Osiris Therapeutics is up 8.9%, or 47c, to $5.73 :theflyonthewall.com |
| | 08:42 EDT | | OSIR |
| | 05:51 EDT | | OSIR |
| theflyonthewall.com: | Osiris Therapeutics to host conference call | | Conference call to discuss marketing clearance from Health Canada for Prochymal will be held on May 18 at 9 am. Webcast Link :theflyonthewall.com |
| | 05:35 EDT | | SNY |
| theflyonthewall.com: | Dr. Reddy's Labs announces the launch of Clopidogrel tablets, USP | | Dr. Reddy’s Laboratories announced that it has launched CLOPIDOGREL TABLETS, USP 75 mg & 300 mg, a bioequivalent generic version of PLAVIX, in the U.S. market on May 18. The ANDAs for Clopidogrel Tablets USP, 75 mg & 300 mg are approved by the U.S. FDA, or USFDA. Dr. Reddy’s Laboratories was among the first applicants to submit a substantially complete ANDA for Clopidogrel Tablets USP, 300 mg with a Paragraph IV certification, and was awarded 180 days of marketing exclusivity for this strength. The PLAVIX brand had U..S. sales of approximately $6.740B for the most recent twelve months ending March 2012 according to IMS Health. :theflyonthewall.com |
|
|
May 17, 2012
|
| 16:38 EDT | | OSIR |
| | 15:47 EDT | | SNY |
| | 13:43 EDT | | SNY |
|
|
May 16, 2012
|
| 12:54 EDT |  | SNY |
|
|
May 15, 2012
|
| 10:09 EDT | | SNY |
| | 09:38 EDT |  | SNY |
| theflyonthewall.com: | Amylin takeover could get done in mid-$30's per share, says Leerink | | Leerink is not surprised by the number of potential bidders reportedly interested in Amylin (AMLN) and says a deal for the company could get done reasonably in the mid-$30 per share range for the right acquirer. The firm thinks a bidding war could push the takeover price even higher. Leerink views Amylin as being the most strategic for Sanofi (SNY), followed by Merck (MRK), and believes and Bristol-Myers' (BMY) purported $22 per share bid sets a floor for any acquisition offer. :theflyonthewall.com |
| | 07:24 EDT | | SNY |
| | 06:10 EDT | | SNY |
|
|
|
|
|
Subscribe for More Information